Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 2,209 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Melanoma Neoplasms Clear all
Terminated Phase 2 Interventional Results available

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

NCT01874119
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Fosaprepitant
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 1 Interventional

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

NCT00002854
View directory record Official record
Conditions
Cancer
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Nov 4, 2026, 5:23 PM EST
Terminated No phase listed Observational

Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

NCT05848219
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 1Phase 2 Interventional

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

NCT04364230
View directory record Official record
Conditions
Melanoma, Ocular Melanoma, Uveal Melanoma
Interventions
6MHP, NeoAg-mBRAF, PolyICLC, CDX-1140
Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Cleveland, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Nov 4, 2026, 5:23 PM EST
Completed No phase listed Observational

Registry Study for Talimogene Laherparepvec

NCT02173171
View directory record Official record
Conditions
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
Interventions
Information collection
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 2 Interventional

Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery

NCT00014092
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, recombinant interferon alfa, sargramostim, temozolomide
Biological · Drug
Lead sponsor
WVU Medicine Thomas Hospitals
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
3
States / cities
San Francisco, California • Santa Monica, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Nov 4, 2026, 5:23 PM EST
Terminated Phase 1 Interventional

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

NCT06299163
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
Interventions
NM32-2668
Biological
Lead sponsor
Numab Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 3 Interventional Results available

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

NCT00111007
View directory record Official record
Conditions
Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Nov 4, 2026, 5:23 PM EST
Terminated Phase 1 Interventional

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

NCT01876641
View directory record Official record
Conditions
Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
Interventions
Vemurafenib + Cobimetinib, Decitabine
Drug
Lead sponsor
Mohammed M Milhem
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 3 Interventional Results available

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
815 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 4, 2026, 5:23 PM EST
Terminated Phase 3 Interventional

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

NCT01280565
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Masitinib, Dacarbazine
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 1 Interventional

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

NCT03052205
View directory record Official record
Conditions
Refractory Solid Tumors, Melanoma
Interventions
IMO-2125
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Nov 4, 2026, 5:23 PM EST
Active, not recruiting Phase 3 Interventional

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291
View directory record Official record
Conditions
Melanoma
Interventions
Fianlimab, Cemiplimab, Pembrolizumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
La Jolla, California • San Francisco, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 4, 2026, 5:23 PM EST
Withdrawn Phase 1 Interventional

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374
View directory record Official record
Conditions
Melanoma
Interventions
AntiCD137, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Nov 4, 2026, 5:23 PM EST
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 4, 2026, 5:23 PM EST
Terminated Phase 2 Interventional Results available

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

NCT00612222
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Nov 4, 2026, 5:23 PM EST
Active, not recruiting Phase 1 Interventional

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

NCT04572451
View directory record Official record
Conditions
Melanoma, Unresectable Solid Tumors, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Antineoplastic Agents, Immunological, Antineoplastic Agents, Immune Checkpoint Inhibitors, Molecular Mechanisms of Pharmacological Action, Nivolumab
Interventions
nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 4, 2026, 5:23 PM EST
Not yet recruiting Not applicable Interventional

Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma

NCT07869381
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma
Interventions
Wide Local Excision
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 4, 2026, 5:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Ensuring Communication in Hospice by Oncology Study (ECHO)

NCT02069769
View directory record Official record
Conditions
Ovarian Cancer, Cervical Cancer, Uterine Cancer, Head and Neck Cancer, Sarcoma, Melanoma
Interventions
communication with oncology team
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

NCT00436605
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
New Haven, Connecticut • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 2 Interventional Results available

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

NCT00788775
View directory record Official record
Conditions
Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
Interventions
Nilotinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Santa Monica, California • Aurora, Colorado • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Nov 4, 2026, 5:23 PM EST
Completed Early Phase 1 Interventional

Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma

NCT02316795
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Cancer of the Breast, Melanoma, Malignant Melanoma
Interventions
Sentinel lymph node biopsy, Goggle-based device with light-emitting diodes (LED), Indocynanine Green
Procedure · Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 1 Interventional

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03071757
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
La Jolla, California • Sacramento, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Nov 4, 2026, 5:23 PM EST
Completed Phase 2 Interventional

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

NCT00338130
View directory record Official record
Conditions
Melanoma
Interventions
AZD6244, Temozolomide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Santa Monica, California • Aurora, Colorado • Miami Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Nov 4, 2026, 5:23 PM EST